Showing 7501-7510 of 8649 results for "".
- Oxurion Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of DMEhttps://modernod.com/news/oxurion-completes-patient-enrollment-for-part-a-of-phase-2-study-evaluating-thr-149-for-treatment-of-dme/2479273/Oxurion NV announced the completion of patient enrollment into Part A of its two part phase 2 study (KALAHARI) evaluating multiple injections of THR-149 for the treatment of DME. Dose selection data from Part A of the study is expected in the second half of 2021. THR-149, Oxurion’s most ad
- Nanoscope’s Optogenetic Gene Therapy Restores Clinically Meaningful Vision in 11 Patients Blinded by Retinitis Pigmentosahttps://modernod.com/news/nanoscopes-optogenetic-gene-therapy-restores-clinically-meaningful-vision-in-11-patients-blinded-by-retinitis-pigmentosa/2479261/Nanoscope Therapeutics announced that vision improvements for all evaluated advanced retinitis pigmentosa (RP) patients persisted through 1 year following a single intravitreal injection in a phase 1/2a clinical study with MCO. “We expect to begin the first randomized, placebo-contro
- Salvat Completes Phase 3 Clinical Trials of its New Ophthalmic Corticosteroid Nanoemulsionhttps://modernod.com/news/salvat-completes-phase-3-clinical-trials-of-its-new-ophthalmic-corticosteroid-nanoemulsion/2479254/Salvat has completed the phase 3 clinical trials in the US for its drug candidate for the treatment of ocular inflammation and pain after cataract surgery. The clinical trials started in 2020 and include 400 adult patients who had recently undergone cataract surgery in 50 US hospitals. Res
- Johnson & Johnson Vision Expands “Sight For Kids” Program and Unveils “Vision for Good” Community Impact Reporthttps://modernod.com/news/johnson-johnson-vision-expands-sight-for-kids-program-and-unveils-vision-for-good-community-impact-report/2479256/Johnson & Johnson Vision announced the expansion of nonprofit program
- WHO Grants Emergency Listing to Sinovac’s Coronavirus Vaccinehttps://modernod.com/news/who-grants-emergency-listing-to-sinovacs-coronavirus-vaccine/2479253/The World Health Organization (WHO) issued an emergency-use listing for Sinovac’s inactivated COVID-19 vaccine CoronaVac in adults aged 18 and over, the second such authorization it has granted to a Chinese company, and the seventh listing overall, according to a FirstWord report. Sinopharm
- Notal Vision Raises Up to $60 Million to Support Development of its Home OCT Technologyhttps://modernod.com/news/notal-vision-raises-up-to-60-million-to-support-development-of-its-home-oct-technology/2479251/Notal Vision announced the closing of a Series D financing to support the commercial growth of the company’s current service, the ForeseeHome AMD Monitoring Program, as well as the go-to-market strategy for its Home OCT pipeline technology. The financing was co-led by Soleus Capital and the compa
- Neurophth Therapeutics and Hopstem Biotechnology Partner to Develop Human Induced Pluripotent Stem Cell-Derived Therapies for Ocular Diseaseshttps://modernod.com/news/neurophth-therapeutics-and-hopstem-biotechnology-partner-to-develop-human-induced-pluripotent-stem-cell-derived-therapies-for-ocular-diseases/2479248/Neurophth Biotechnology and Hopstem Biotechnology announced a strategic partnership aiming to provide human iPSC-derived cell therapy for ocular diseases. The partnership leverages Neurophth’s experience in global gene/cell therapy drugs development and understanding of ophthalmic di
- Nicox’s Completes Pre-Defined Enrollment of NCX 4251 Mississippi Phase 2b Blepharitis Trialhttps://modernod.com/news/nicoxs-completes-pre-defined-enrollment-of-ncx-4251-mississippi-phase-2b-blepharitis-trial/2479250/Nicox announced that more than 200 patients, the pre-defined target, have been randomized in the NCX 4251 Mississippi phase 2b blepharitis clinical trial. Topline results are expected to be announced during September 2021. “Blepharitis is a highly prevalent eye condition with frequent exac
- GSK, Sanofi Start Phase 3 Study of COVID-19 Vaccine Candidatehttps://modernod.com/news/gsk-sanofi-start-phase-3-study-of-covid-19-vaccine-candidate/2479245/GlaxoSmithKline and Sanofi announced Thursday the start of enrollment in a phase 3 study investigating their adjuvanted recombinant-protein COVID-19 vaccine candidate, according to a FirstWord report. The trial will include more than 35,000 volunteers aged 18 and older from several countries, inc
- Scientists: New Research May Revolutionize Cataract Treatmenthttps://modernod.com/news/scientists-new-research-may-revolutionize-cataract-treatment/2479235/Eye experts have made a breakthrough that could potentially change the way cataracts are treated – with potential for drug therapy to replace surgery. A team of international scientists, led by Professor Barbara Pierscionek of Anglia Ruskin University (ARU), has published